Möchten Sie immer auf dem neuesten Stand bleiben?

The Stock Markets are opening with a strong crosscurrent of AI-powered drug discovery, cross-border biologics distribution, and capital structure resets

Ottawa, Feb. 25, 2026 (GLOBE NEWSWIRE) -- According to Precedence Research, the global type 2 diabetes market size is predicted to reach around USD 79.25 billion by 2035, increasing from USD 43.29...

Delivered first clinical validation of the Recursion full stack AI Operating System in FAP, demonstrating translation from AI-driven biological insight to meaningful patient outcomes; multiple...

Dublin, Feb. 25, 2026 (GLOBE NEWSWIRE) -- The "Enterprise Tech Ecosystem Series: Sanofi S.A. 2025" company profile has been added to ResearchAndMarkets.com's offering. The report provides...

Comprehensive VAX-31 Adult Phase 3 Clinical Program, Finalized in Consultation and Alignment with FDA, Advances with Three Phase 3 Studies Underway to Support Planned BLA Submission Topline Safety,...

MYQORZO® Approved for Adults with Symptomatic Obstructive HCM in U.S., China and Europe; U.S. Launch Underway with First Prescriptions Dispensed within Days of Drug Availability Supplemental NDA for...

Kraig Biocraft Laboratories (OTCQB: KBLB) is currently the National Geographic March issue cover feature, which highlights major spider silk science breakt

Dupixent de Sanofi et Regeneron est approuvé aux États-Unis comme le premier et le seul médicament pour la rhinosinusite fongique allergique Approbation chez les adultes et les enfants âgés de 6 ans...

Sanofi and Regeneron’s Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis Approval in adults and children aged 6 years and older supported by phase 3 study...

Approval in adults and children aged 6 years and older supported by Phase 3 trial demonstrating Dupixent significantly reduced nasal signs and symptoms, and systemic corticosteroid use or surgery...